Targeted Oncology Staff

During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the GRIFFIN, MASTER, and PERSEUS trials in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

In the first article of a 2-part series, Marc S. Hoffmann, MD, looks at the factors to take into consideration before initiating another line of treatment in patients with chronic lymphocytic leukemia.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sharad A. Ghamande, MD, discussed the significance of the NRG-GY018/KEYNOTE-868 and RUBY trials of immune checkpoint inhibitor plus chemotherapy in patients with advanced endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed with participants which symptoms of myelofibrosis impact their quality of life and how they would treat a patient experiencing anemia.

In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

In a discussion with Peers & Perspectives in Oncology, Jeff Allen, PhD, explains the important work of Friends of Cancer Research in crafting policy to better optimize care for patients with cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.

At a live virtual event, Arlene O. Siefker-Radtke, MD, looked at the newer treatment strategies available for patients with advanced bladder cancer including sacituzumab govitecan.

In the first article of a 2-part series, Christine Bestvina, MD, discussed the role of the newer tyrosine kinase inhibitor repotrectinib for patients with non–small cell lung cancer that is positive for a ROS1 mutation.

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, asked participants to share their experiences using nivolumab plus cabozantinib in patients with advanced renal cell carcinoma. This is the second of 2 articles based on this event.

In the first article in a 2-part series, William J. Gradishar, MD, discusses the importance of elacestrant for treating patients with ESR1 positive metastatic breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, asked participants how they would approach therapy for a patient with metastatic non–small cell lung cancer when biomarker testing is not yet completed. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on key takeaways from frontline combination trial data in patients with metastatic renal cell carcinoma. This is the second of 2 articles based on this event.

In the first article of a 2-part series, Farrukh Awan, MD, discusses the current landscape of treatment for patients with chronic lymphocytic leukemia and what Burton tyrosine kinase inhibitors are having the most impact for these patients.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed the importance of overall survival data in JAK inhibitor trials and how to transition between agents. This is the second of 2 articles based on this event.

In a discussion with Targeted Oncology, Michael Gibson, MD, PhD, discusses the benefits of using a patient’s PD-L1 combined positive score to determine if they are given nivolumab and chemotherapy to treat their gastric cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed what patient factors and other considerations affect the choice of immunotherapy for patients with advanced BRAF-negative melanoma. This is the first of 2 articles based on this event.

In the second article of a 2-part series, Lori Muffly, MD, MS, leads a discussion on how treatment considerations change when a patient has severe graft-vs-host disease or if the involvement is in the lung and where ruxolitinib fits into treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Andrew Kuykendall, MD, reviewed adverse events and dosing issues related to the 4 approved JAK inhibitors in patients with myelofibrosis.

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Hatim Husain, MD, explained the significance of the PACIFIC trial and its real-world counterpart PACIFIC-R looking at the use of durvalumab after chemotherapy and radiation in patients with unresectable stage III non–small cell lung cancer.

In 2 separate live virtual events, Firas B. Badin, MD, MBA, and Sandip P. Patel, MD, review a case of a patient with non–small cell lung cancer with their respective groups and discuss the best options for therapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, examined the impact of the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab and nivolumab/cabozantinib in patients with advanced renal cell carcinoma. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joyce O'Shaughnessy, MD, reviewed the current state of CDK4/6 inhibitor therapy for patients with advanced estrogen-receptor positive breast cancer.

In the first article of a 2-part series, Vamsidhar Velcheti, MD, MBA, discussed why patients with lung cancer may experience dizziness with repotrectinib and why the efficacy data behind this therapy are considered impressive.

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, held a discussion on the use of biomarker testing in patients with advanced non–small cell lung cancer. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Maria Bell, MD, MPH, MBA, moderated a discussion on biomarker testing and treatment for a patient with extensive, well-differentiated, grade 1 endometrioid adenocarcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, and other oncologists discussed the role of chemotherapy plus dual immunotherapy in patients with non–small cell lung cancer.

At a live virtual event, David Rizzieri, MD, CPE, provided commentary on the landscape of treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

In the second part of a 2-article series, Matthew A. Lunning, DO, FACP, leads a discussion on how to best manage toxicities from tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.